Who we are

Epimac is an EU funded Training Network for young researchers, focussing on new medicine development in the area of epigenetics

Read more
What we do

In Epimac, we focus on a new class of medicine to be eveloped for immuun cells that gotten out of control, such as seen in IBD.

Read more

We provide an unique collaboration between AMC, academic partners, GSK, Eureka Institute and Gut Research in the Netherlands.

Read more
Latest Publications

Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. Find out more on PubMed.

Read more

About Us & What We Do

Epigenetic marks on the DNA are critical in regulating gene expression, and allow cells to differentiate and respond to environmental stimuli.

The importance of these epigenetic marks in inflammation and cancer is evident, and molecules have been newly developed to intervene with these marks (Nicodeme et al, Nature 2011; Kruidenier et al, Nature 2012; Ntziachristos et al, Nature 2014).

Such compounds turn out to have extremely anti-inflammatory effects in macrophages, dendritic cells and monocytes, as well as in their target cells (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012).

Meet Our Key Team

Latest Publications


Tytgat Instituut


Gut Research is a research group that is part of the Tytgat Institute for Liver and Intestinal Research, and the Dept. of Gastroenterology at the Academic Medical Center (AMC) in Amsterdam. We are a group of research fellows, master students, basic researchers and physicians that hope to bridge basic research and drug development. Click on the link for more information about the Tytgat Institute or GutResearch.

Medical Biochemistry


Inflammation is a hallmark of atherosclerosis and correlates with plaque progression, severity and stability. The abundance of inflammatory cells, and more specifically macrophages often as lipid laden foam cells, associates with key features of plaque instability and circulating inflammatory markers are good predictors of clinical disease outcome. Click on the link for more information about Medical Biochemistry.

GSK Epinova


GSK is a global-healtcare company and develops several medicines to treat acute and chronic diseases. Rab Prinjha leads the Epinova epigenetics Discovery Performance Unit in the Immuno-Inflammation therapy area (II-TA). Click on the link for more information about GSK.

Clinical genetics


The department of Clinical Genetics is dedicated to fast, reliable, high quality laboratory diagnostics and genetic counseling. Therefore evaluation and implementation of innovative genetic laboratory diagnostic strategies and of new approaches in genetic counseling are regarded as main issues of research. Click on the link for more information about Clinical Genetics.

What our researchers say


“I believe the most exciting aspect of Epimac is the collaborative nature of the project, where I am capable of using the strengths from the academic hospital as well as the pharmaceutical industry in elucidating the role of the epigenome in the pathogenesis of inflammatory bowel diseases.”

Rab -

“The central role of macrophages in modulating human disease is well established. Emerging evidence of innate memory and macrophage plasticity requiring epigenetic processes makes Epimac an incredibly timely and exciting collaboration.”

eu flag

Horizon2020 collaborations

Funded by the Horizon 2020 Framework Programme of the European Union.